João Pedro Moura Guedes1, Nuno Marques2, Pedro Azevedo3, Teresa Mota3, João Bispo3, Raquel Fernandes3, Hugo Costa4, Hugo Vinhas4, Jorge Mimoso2, Ilídio de Jesus4. 1. Centro Hospitalar Universitário do Algarve, Faro, Portugal; Algarve Biomedical Center, Faro, Portugal; Registo Nacional de Síndromes Coronárias Agudas, Sociedade Portuguesa de Cardiologia, Lisboa, Portugal. Electronic address: jptuna7@gmail.com. 2. Centro Hospitalar Universitário do Algarve, Faro, Portugal; Algarve Biomedical Center, Faro, Portugal; Departamento de Ciências Biomédicas e de Medicina da Universidade do Algarve, Faro, Portugal; Registo Nacional de Síndromes Coronárias Agudas, Sociedade Portuguesa de Cardiologia, Lisboa, Portugal. 3. Centro Hospitalar Universitário do Algarve, Faro, Portugal; Algarve Biomedical Center, Faro, Portugal; Registo Nacional de Síndromes Coronárias Agudas, Sociedade Portuguesa de Cardiologia, Lisboa, Portugal. 4. Centro Hospitalar Universitário do Algarve, Faro, Portugal; Algarve Biomedical Center, Faro, Portugal.
Abstract
INTRODUCTION AND OBJECTIVES: In ST-segment elevation myocardial infarction (STEMI) the benefit of dual antiplatelet therapy is unequivocal, but the optimal time to administer the loading dose (LD) of a P2Y12 inhibitor is the subject of debate and disagreement. The main aim of this study was characterize current practice in Portugal and to assess the prognostic impact of P2Y12 inhibitor LD administration strategy, before versus during or after primary percutaneous coronary intervention (PCI). METHODS: This multicenter retrospective study based on the Portuguese National Registry on Acute Coronary Syndromes included patients with STEMI and PCI performed between October 1, 2010 and September 19, 2017. Two groups were established: LD before PCI (LD-PRE) and LD during or after PCI (LD-CATH). RESULTS: A total of 4123 patients were included, 66.3% in the LD-PRE group and 32.4% in the LD-CATH group. Prehospital use of a P2Y12 inhibitor was a predictor of the composite bleeding endpoint (major bleeding, need for transfusion or hemoglobin [Hb] drop >2g/dl), Hb drop >2g/dl and reinfarction. There were no differences between groups in major adverse events (MAE) (in-hospital mortality, reinfarction and stroke) or in-hospital mortality. CONCLUSIONS: Prehospital use of a P2Y12 inhibitor was associated with an increased risk of bleeding, predicting the composite bleeding outcome and Hb drop >2g/dl, with no differences in mortality or MAE, calling into question the benefit of this strategy.
INTRODUCTION AND OBJECTIVES: In ST-segment elevation myocardial infarction (STEMI) the benefit of dual antiplatelet therapy is unequivocal, but the optimal time to administer the loading dose (LD) of a P2Y12 inhibitor is the subject of debate and disagreement. The main aim of this study was characterize current practice in Portugal and to assess the prognostic impact of P2Y12 inhibitor LD administration strategy, before versus during or after primary percutaneous coronary intervention (PCI). METHODS: This multicenter retrospective study based on the Portuguese National Registry on Acute Coronary Syndromes included patients with STEMI and PCI performed between October 1, 2010 and September 19, 2017. Two groups were established: LD before PCI (LD-PRE) and LD during or after PCI (LD-CATH). RESULTS: A total of 4123 patients were included, 66.3% in the LD-PRE group and 32.4% in the LD-CATH group. Prehospital use of a P2Y12 inhibitor was a predictor of the composite bleeding endpoint (major bleeding, need for transfusion or hemoglobin [Hb] drop >2g/dl), Hb drop >2g/dl and reinfarction. There were no differences between groups in major adverse events (MAE) (in-hospital mortality, reinfarction and stroke) or in-hospital mortality. CONCLUSIONS: Prehospital use of a P2Y12 inhibitor was associated with an increased risk of bleeding, predicting the composite bleeding outcome and Hb drop >2g/dl, with no differences in mortality or MAE, calling into question the benefit of this strategy.
Keywords:
Dose de carga.; Enfarte agudo do miocárdio com supradesnivelamento do segmento ST; Inibidor do recetor P2Y12; Loading dose; P2Y(12) inhibitor; ST‐segment elevation myocardial infarction
Authors: Leonid N Maslov; Sergey V Popov; Alexandr V Mukhomedzyanov; Ivan A Derkachev; Vyacheslav V Ryabov; Alla A Boshchenko; N Rajendra Prasad; Galina Z Sufianova; Maria S Khlestkina; Ilgiz Gareev Journal: Korean Circ J Date: 2022-10 Impact factor: 3.101